HOME >> BIOLOGY >> NEWS
Hope remains for Alzheimer's sufferers

The National Institute of Clinical Excellence (NICE), who last week rejected appeals to allow patients with mild Alzheimer's to receive the life-changing medication donepezil (Aricept), will hopefully re-appraise their decision in three-years time, according to neurologist Professor Robert Kerwin in an article published in the November issue of the medical journal Future Neurology.

Kerwin evaluated recent research published in the Lancet that may not have been taken into account by the NICE committee. In this study, nursing home patients with severe Alzheimer's disease were administered with donepezil, or a placebo drug, and were observed for 6-months. Those patients receiving donepezil treatment showed significantly improved cognitive function, compared with those patients not receiving the drug, despite recommendations by NICE not to prescribe donepezil to this patient group.

Kerwin also evaluates recent data suggesting that the drugs are effective in patients with milder forms of Alzheimer's disease. The recent 2005 NICE revised guidelines for cholinesterase inhibitors, the class of drug that donepezil and other Alzheimer drugs rivastigmine(Exelon/Prometax) and galantamine (Reminyl) belong to, state that these drugs can only be administered to patients with moderate Alzheimer's, for whom NICE believe the evidence is strongest. At the same time NICE withdrew its recommendations for the use of these drugs for patients with mild-to-moderate Alzheimer's. Memantime (Exiba), belonging to another class of drugs, is not recommended to Alzheimer's sufferers, but is restricted to ongoing clinical trials and may be possible treatment in the future.

"NICE's decisions are based upon the economic health calculations that they do, which are balanced against clinical benefit. Even though the drugs do work in the long-term, patients do progress to requirements of alternative care that do not necessarily lead to savings within the NHS." Commented K
'"/>

Contact: Jenny Beard
j.beard@futuremedicine.com
20-834-92033
Future Science Group
30-Oct-2006


Page: 1 2 3

Related biology news :

1. Journal of Nuclear Medicines impact grows, remains consistently high over past 5 years
2. UI anthropologist, colleagues discover remains of earliest giant panda
3. Prehistoric remains reveal a drastic shift in northern fur seal ecology
4. Researcher to determine why oil still remains from Exxon Valdez
5. Genetic research remains hidden
6. Students discover 11,000 year old remains of Irish Elk
7. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
8. Link identified between Alzheimers disease and glaucoma
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Journal of Alzheimers Disease achieves significant impact factor
11. Alzheimers prevention role discovered for prions

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/11/2020)... FORT LAUDERDALE, Fla. (PRWEB) , ... March 11, ... ... Commission Accredited teleradiology and telemedicine company backed by Siemens Healthineers and several healthcare ... has already infected over 100,000 people in over 100 countries and has caused ...
(Date:3/5/2020)... SAN DIEGO (PRWEB) , ... March 05, 2020 ... ... Inc. today announced a strategic partnership agreement with Phoenestra GmbH to accelerate Cytonus’ ... biotech company founded in San Diego, California. Phoenestra is a biotech company located ...
(Date:3/5/2020)... ... , ... In September 2016, stem cell biotechnology company Asymmetrex ... first, and still only, available technology that provides the cell-specific count or dose ... the number and quality of therapeutic tissue stem cells are unable to distinguish ...
Breaking Biology News(10 mins):
(Date:2/11/2020)... ... February 11, 2020 , ... ... results from a long-term follow-up clinical study of outpatient L4-L5 lumbar interspinous ... LLC). Unlike extension block design, the Inspan device fixates the spine to ...
(Date:2/10/2020)... ... ... R3 Medical Training announced it is now registering for its next Comprehensive ... is hands on involving real patients and stem cell biologics, with every attendee receiving ... Training Course has received rave reviews from attendees, who love the hands on nature ...
(Date:2/5/2020)... ... 05, 2020 , ... Rare Disease Day® , held the last day ... Rare Disorders (NORD), to raise awareness amongst the general public and decision-makers about rare ... “Behind The Mystery” rare disease series will be shining the light on ...
(Date:2/3/2020)... ... February 03, 2020 , ... ... Cambridge, MA, announce that OmniType, the 11-locus, single tube multiplex successor to Holotype ... a best-in-class product featuring locus-multiplexing and short library preparation, for HLA genotyping from ...
Breaking Biology Technology:
Cached News: